title: Personalised medicine in cystic fibrosis must be made affordable.
abstract: The recent introduction of mutation specific therapy to a small group of patients with Cystic Fibrosis has created the debate about the affordability of personalised medicine. I would argue strongly that the NHS must find a way to make revolutionary mutation specific therapies available to patients and explore the routes that all parties must explore to facilitate this. A process which engages industry, providers and patients will provide the best long term answers.
authors.affiliation: Department of Respiratory Medicine, Royal Brompton Hospital, Sydney Street, London SW3 6NP. Electronic address: d.bilton@rbht.nhs.uk.
authors.forename: Diana
authors.initials: D
authors.lastname: Bilton
mesh_terms: D000328:Adult; D002648:Child; D003365:Costs and Cost Analysis; D003550:Cystic Fibrosis / Q000191:economics* / Q000628:therapy*; D006801:Humans; D057285:Precision Medicine / Q000191:economics*
keywords: Cystic Fibrosis; Personalised Medicine